At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 198 enrolled
Drug / intervention
IC51biological
Likely dose
IC51 6 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 on Long Term Immunogenicity. An Uncontrolled, Open-label Phase 3 Study.
In Brief
A Phase 3 clinical trial evaluating IC51 for Japanese Encephalitis. Completed, enrolled 198 participants across 3 sites in 2 countries.
Detailed Summary
The objective is to assess the effect of a booster vaccination on immunogenicity of IC51 in terms of seroconversion rate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Encephalitis
CountriesAustria, Germany
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedJan 2008
Primary CompletionOct 2009
TodayJul 2026
First PostedJan 16, 2008
Enrollment StartDec 1, 2007
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.5 years ago
Interventions
IC51biological
IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization